New Directions With PARP Inhibitors in Pancreatic Cancer

In this episode, Eileen M. O’Reilly, MD, and Naureen Starling, MD, FRCP,  discuss emerging therapeutic strategies involving PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:

• Current treatment landscape and testing in the United States vs the United Kingdom  
• Testing for molecular subgroups beyond BRCAm
• Using PARP inhibitors in earlier stages of the disease
• Learning from other cancers, such as prostate, breast, and ovarian  

Presenters:

Eileen M. O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary/Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College
New York, New York, USA

Naureen Starling, MD, FRCP
Associate Director of Clinical Research
Department of GI Cancers
Consultant Medical Oncologist, GI Cancers
The Royal Marsden Hospital
London, United Kingdom

Content based on an online CME program supported by an educational grant from AstraZeneca.

Link to full program:
https://bit.ly/3s6AnSz

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.